STAT3 Contributes a Favorable Response to Pembrolizumab Through IFN-γ-induced Apoptosis in Urothelial Cancer

HIROTAKA FUCHIZAWA; KIYOHIRO ANDO; NORIKO MOTOI; TOSHIHIKO IIZUKA; MASAHARU INOUE; KOUKI MITANI; YUTA SANO; HISANORI TAKENOBU; MASAYUKI HARUTA; RITSUKO ONUKI; YOH MATSUOKA; TAKEHIKO KAMIJO; YUKIO KAGEYAMA

doi:10.21873/anticanres.16994

Research ArticleExperimental Studies

STAT3 Contributes a Favorable Response to Pembrolizumab Through IFN-γ-induced Apoptosis in Urothelial Cancer

HIROTAKA FUCHIZAWA, KIYOHIRO ANDO, NORIKO MOTOI, TOSHIHIKO IIZUKA, MASAHARU INOUE, KOUKI MITANI, YUTA SANO, HISANORI TAKENOBU, MASAYUKI HARUTA, RITSUKO ONUKI, YOH MATSUOKA, TAKEHIKO KAMIJO and YUKIO KAGEYAMA

Anticancer Research May 2024, 44 (5) 1925-1930; DOI: https://doi.org/10.21873/anticanres.16994

HIROTAKA FUCHIZAWA

1Department of Urology, Saitama Cancer Center, Saitama, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

KIYOHIRO ANDO

2Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: kiyohiro_ando@saitama-pho.jp

NORIKO MOTOI

3Department of Pathology, Saitama Cancer Center, Saitama, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

TOSHIHIKO IIZUKA

3Department of Pathology, Saitama Cancer Center, Saitama, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

MASAHARU INOUE

1Department of Urology, Saitama Cancer Center, Saitama, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

KOUKI MITANI

1Department of Urology, Saitama Cancer Center, Saitama, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

YUTA SANO

1Department of Urology, Saitama Cancer Center, Saitama, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

HISANORI TAKENOBU

2Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

MASAYUKI HARUTA

2Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

RITSUKO ONUKI

2Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

YOH MATSUOKA

1Department of Urology, Saitama Cancer Center, Saitama, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

TAKEHIKO KAMIJO

2Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

YUKIO KAGEYAMA

1Department of Urology, Saitama Cancer Center, Saitama, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Info & Metrics
PDF

Article Information

vol. 44 no. 5 1925-1930

DOI

https://doi.org/10.21873/anticanres.16994

PubMed

38677727

Published By

International Institute of Anticancer Research

Print ISSN

0250-7005

Online ISSN

1791-7530

History

Received March 15, 2024
Revision received March 28, 2024
Accepted March 29, 2024
Published online April 27, 2024.

Author Information

HIROTAKA FUCHIZAWA¹,*,
KIYOHIRO ANDO²,*⇑,
NORIKO MOTOI³,
TOSHIHIKO IIZUKA³,
MASAHARU INOUE¹,
KOUKI MITANI¹,
YUTA SANO¹,
HISANORI TAKENOBU²,
MASAYUKI HARUTA²,
RITSUKO ONUKI²,
YOH MATSUOKA¹,
TAKEHIKO KAMIJO² and
YUKIO KAGEYAMA¹

¹Department of Urology, Saitama Cancer Center, Saitama, Japan;
²Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan;
³Department of Pathology, Saitama Cancer Center, Saitama, Japan

Correspondence to: Kiyohiro Ando, MD, Ph.D., Research Institute for Clinical Oncology, Saitama Cancer Center, 818 Komuro, Inamachi, Kitaadachi-gun, Saitama 362-0806, Japan. E-mail: kiyohiro_ando{at}saitama-pho.jp

↵* These Authors contributed equally to this study.

View Full Text

Statistics from Altmetric.com

Cited By...

1 Citations
Citations
Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

PreviousNext

In this issue

Anticancer Research

Vol. 44, Issue 5

May 2024

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Back Matter (PDF)
Ed Board (PDF)
Front Matter (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following STAT3 Contributes a Favorable Response to Pembrolizumab Through IFN-γ-induced Apoptosis in Urothelial Cancer

Message Subject (Your Name) has sent you a message from Anticancer Research

Message Body (Your Name) thought you would like to see the Anticancer Research web site.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Math question * 2 + 5 =

Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

Citation Tools

STAT3 Contributes a Favorable Response to Pembrolizumab Through IFN-γ-induced Apoptosis in Urothelial Cancer

Anticancer Research May 2024, 44 (5) 1925-1930; DOI: 10.21873/anticanres.16994

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Reprints and Permissions

STAT3 Contributes a Favorable Response to Pembrolizumab Through IFN-γ-induced Apoptosis in Urothelial Cancer

Anticancer Research May 2024, 44 (5) 1925-1930; DOI: 10.21873/anticanres.16994

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Jump to section

Article
Figures & Data
Info & Metrics
PDF

No related articles found.

PubMed
Google Scholar

Cited By...

No citing articles found.

Google Scholar

Keywords

Pembrolizumab
Urothelial carcinoma
STAT3
IFN-γ

Main menu

User menu

Search

STAT3 Contributes a Favorable Response to Pembrolizumab Through IFN-γ-induced Apoptosis in Urothelial Cancer

Article Information

Author Information

Statistics from Altmetric.com

Cited By...

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords